BORTEZOMIB 1 mg/mL Injection, Powder, Lyophilized, For Solution, 1 vial
by Zydus Lifesciences Limited · 1 VIAL, SINGLE-DOSE in 1 CARTON (70771-1708-1) / 3.5 mL in 1 VIAL, SINGLE-DOSE
NDC 70771-1708-01
🏷️ FDA NDC (as labeled)
70771-1708-1
billing pads the package segment with a zero
Rx only
Generic
On market
Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →
🆔 Identity & classification
FDA NDC (as labeled)
70771-1708-1
Product NDC
70771-1708
11-digit billing NDC
70771170801
RxCUI
402243
UNII
69G8BD63PP
Application #
ANDA210204
SPL Set ID
582c7c0d-fa25-4586-8157-a1e2653d72d9
Established class (EPC)
Proteasome Inhibitor
Mechanism of action
Proteasome Inhibitors
DEA schedule
Non-controlled
Marketing category
ANDA
Marketing status
On market
FDA listing status
Listed (active directory)
Marketing start
2022-05-02
Route
INTRAVENOUS, SUBCUTANEOUS
Dosage form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Substance
BORTEZOMIB
TE code (Orange Book)
AP · RLD · RS
Why two NDCs?
The FDA registers this code as 70771-1708-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 70771-1708-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.
🏷️ RxNorm drug class
This medicine belongs to the Proteasome Inhibitor class.
Pharmacologic class
Proteasome Inhibitor
Drug family (ATC)
Proteasome inhibitors
How it works
Proteasome Inhibitors
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.
🏭 Manufacturer & labeler
LabelerZydus Lifesciences Limited
Application holderZYDUS PHARMACEUTICALS USA INC
FDA applicationANDA210204 (ANDA)
Labeler code70771
First marketedMay 2022
Product typeHuman Prescription Drug
Portfolio717 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.
🩺 Clinical
📗 Our plain-language guide HelloPharmacist
- Bortezomib is a cancer treatment, but it's not a traditional chemotherapy drug. It belongs to a class called proteasome inhibitors. Instead of directly attacking DNA like older che...
- What exactly is bortezomib treating — is it a chemotherapy drug?
- Yes, bortezomib is always given by injection in a clinical setting — either into a vein (IV) or just under the skin (subcutaneous injection) — by a trained healthcare professional....
- How is bortezomib given — do I have to go to a clinic every time?
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Bortezomib — tap one for details:
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.
💬 Questions about BORTEZOMIB?
Ask a pharmacist →
Ask a licensed pharmacist directly — free, answered by our team.
🧪 Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 3OWL53L36A
A natural sugar alcohol derived from seaweed or synthesized in the lab. It's used as a filler to add bulk, a sweetener in sugar-free formulas, and a disintegrant to help tablets break apart in the stomach.
1 inactive ingredient listed in the exact product block matched to this NDC.
Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed —
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.
💲 Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.
🔁 Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| bortezomib 3.5 mg 00143-9098-01 | Hikma | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 00409-1700-01 | Hospira, | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 25021-0262-10 | Sagent | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 31722-0303-31 | Camber | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 43598-0426-60 | Dr.Reddy's | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 51817-0586-01 | Pharmascience | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 55150-0337-01 | Eugia | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 60505-6050-04 | Apotex | 1 vial | — | AP | FDA listed | — |
| Velcade 3.5 mg 63020-0049-01 | Takeda | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 63323-0821-10 | Fresenius | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 68001-0534-36 | BluePoint | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 68001-0540-36 | BluePoint | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg/3.5mL 68001-0541-36 | BluePoint | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg/3.5mL 70069-0836-01 | Somerset | 1 vial | — | AP | FDA listed | — |
| Bortezomib 1 mg/mL 70710-1411-01 | Zydus | 1 vial | — | AP | FDA listed | — |
| Bortezomib 1 mg/mLthis 70771-1708-01 | Zydus | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 71288-0118-10 | Meitheal | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg/3.5mL 72205-0183-01 | Novadoz | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 72338-0200-01 | Waverley | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 72603-0270-01 | NorthStar | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 75007-0501-31 | Ningbo | 10 vials | — | AP | FDA listed | — |
| Bortezomib 3.5 mg/3.5mL 83090-0008-01 | Sintetica | 1 vial | — | AP | FDA listed | — |
| Bortezomib 3.5 mg 83634-0208-10 | Avenacy, | 1 vial | — | AP | FDA listed | — |
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.
⏳ Availability & generic status
🏛️
2022
On the market since
May 2022
📍
2026
Currently FDA-listed
4 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.
📊 Medicare Part D spend CMS · PART D · 2026 (Q1)
Medicare Part D (outpatient prescription) spending for Bortezomib — the program that covers self-administered drugs. 10 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Bortezomib. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$459.5K
Claims incl. refills
998
Beneficiaries
438
Spend / beneficiary
$1,049.13
Spend / claim
$460.44
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
🔬 Reported adverse events (FAERS)
Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Bortezomib — the ingredient across all brands.
Top reported reactions
Reporter sex
Serious outcomes
Reports over time (by year) — tap or hover for the count & year
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.
📦 Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Status |
|---|---|---|---|
| 70771-1708-01 You're viewing this | 1 VIAL, SINGLE-DOSE in 1 CARTON (70771-1708-1) / 3.5 mL in 1 VIAL, SINGLE-DOSE | 2022-05-02 | Active |
🧭 About this NDC listing & data coverage
Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.
Questions about this listing
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 70771-1708-1, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 70771-1708-01, written without dashes as 70771170801. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 70771-1708-01, the first segment (70771) is the labeler code FDA assigned to Zydus Lifesciences Limited; the middle segment (1708) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (01) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Zydus Lifesciences Limited. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
Zydus Lifesciences Limited is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
📄 Full prescribing information FDA SPL
The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label ▾
No readable label sections were found for this product.
No label section mentions that — try another word, or open the full label on DailyMed below.
Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.
Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published
NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.